The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

Autor: Hardaker EL; Oncology R&D, AstraZeneca, Cambridge, UK., Sanseviero E; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Karmokar A; Oncology R&D, AstraZeneca, Cambridge, UK., Taylor D; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Milo M; Oncology R&D, AstraZeneca, Cambridge, UK., Michaloglou C; Oncology R&D, AstraZeneca, Cambridge, UK., Hughes A; Oncology R&D, AstraZeneca, Cambridge, UK., Mai M; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., King M; Oncology R&D, AstraZeneca, Cambridge, UK., Solanki A; Oncology R&D, AstraZeneca, Cambridge, UK., Magiera L; Oncology R&D, AstraZeneca, Cambridge, UK., Miragaia R; Oncology R&D, AstraZeneca, Cambridge, UK., Kar G; Oncology R&D, AstraZeneca, Cambridge, UK., Standifer N; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.; Tempest Therapeutics, Brisbane, CA, USA., Surace M; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Gill S; Oncology R&D, AstraZeneca, Cambridge, UK., Peter A; Oncology R&D, AstraZeneca, Cambridge, UK., Talbot S; Oncology R&D, AstraZeneca, Cambridge, UK., Tohumeken S; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Fryer H; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Mostafa A; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Mulgrew K; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Lam C; Oncology R&D, AstraZeneca, Cambridge, UK., Hoffmann S; Imaging and Data Analytics, AstraZeneca, Cambridge, UK., Sutton D; Imaging and Data Analytics, AstraZeneca, Cambridge, UK., Carnevalli L; Oncology R&D, AstraZeneca, Cambridge, UK., Calero-Nieto FJ; Oncology R&D, AstraZeneca, Cambridge, UK., Jones GN; Oncology R&D, AstraZeneca, Cambridge, UK., Pierce AJ; Oncology R&D, AstraZeneca, Cambridge, UK.; Crescendo Biologics Limited, Cambridge, UK., Wilson Z; Oncology R&D, AstraZeneca, Cambridge, UK., Campbell D; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Nyoni L; Oncology R&D, AstraZeneca, Cambridge, UK., Martins CP; Oncology R&D, AstraZeneca, Cambridge, UK., Baker T; CPSS AST, AstraZeneca, Cambridge, UK., Serrano de Almeida G; CPSS AST, AstraZeneca, Cambridge, UK., Ramlaoui Z; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Bidar A; CPSS, Imaging, AstraZeneca, Gothenburg, Sweden., Phillips B; Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Boland J; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Iyer S; Oncology R&D, AstraZeneca, Boston, MA, USA., Barrett JC; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Loembé AB; Early Clinical Development, AstraZeneca, Oss, the Netherlands., Fuchs SY; Department of Biomedical Sciences, School of Veterinary Medicine University of Pennsylvania, Philadelphia, PA, 19104, USA., Duvvuri U; UPMC Department of Otolaryngology and UPMC Hillman Cancer Center, 200 Lothrop St. Suite 500, Pittsburg, PA, 15213, USA., Lou PJ; National Taiwan University Hospital, No. 7, Chung Shan S. Rd. (Zhongshan S. Rd.), Zhongzheng Dist., Taipei City, 10002, Taiwan., Nance MA; VA Pittsburgh Healthcare System, University Drive C, Pittsburg, PA, 15240, USA., Gomez Roca CA; Institut Claudius Regaud-Cancer Comprehensive Center, 1 Avenue Irene Joliot-Curie, IUCT-O, Toulouse, 31059 Cedex 9, France., Cadogan E; Oncology R&D, AstraZeneca, Cambridge, UK., Critichlow SE; Oncology R&D, AstraZeneca, Cambridge, UK., Fawell S; Oncology R&D, AstraZeneca, Boston, MA, USA., Cobbold M; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Dean E; Oncology R&D, AstraZeneca, Cambridge, UK., Valge-Archer V; Oncology R&D, AstraZeneca, Cambridge, UK., Lau A; Oncology R&D, AstraZeneca, Cambridge, UK., Gabrilovich DI; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA. dmitry.gabrilovich@astrazeneca.com., Barry ST; Oncology R&D, AstraZeneca, Cambridge, UK. simon.t.barry@astrazeneca.com.

Publikováno v: Nature communications [Nat Commun] 2024 Feb 24; Vol. 15 (1), pp. 1700. Date of Electronic Publication: 2024 Feb 24.